A Phase 2/3 interventional study of ABBV-RGX-314 and ABBV-RGX-314 in AMD, nAMD and Wet Age-related Macular Degeneration, sponsored by AbbVie. Active, not recruiting at 89 sites in United States. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Choroidal Neovascularization with a site in United States — 2 open to participants now, 9 under way, 4 of them phase 3. Choroidal Neovascularization · United States.
Among the 88 studies in Choroidal Neovascularization with a site in United States, this one is the 7th largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2020, is one of 6 in phase 2/3, and was the 81st registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →2 of the 88 studies in Choroidal Neovascularization with a site in United States are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in United States, Austria, Brazil and 10 more countries
Ages 50+
EyeBiotech Ltd. · Sites in United States, Argentina, Australia and 9 more countries
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 37 · Phase 3 18 · Phase 4 4
First in 1997; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 671 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 42 across the 77 interventional studies, 77 across the 11 observational. Of the 75 that completed or were terminated, 32 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 88 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 6 studies filed under Choroidal Neovascularization — fewer than ten, so there is no comparison to draw.
2 of the studies in Choroidal Neovascularization with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06125977University of UtahImpact of Non-Exudative Type 1 MNV on AMD Progression | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 88 studies in Choroidal Neovascularization with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to maintain or prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every 4 to 16 weeks in frequency, to maintain efficacy. Due to the burden of these treatments, patients often experience a decline in vision with reduced frequency of treatment over time.
This randomized, partially masked, active-controlled, Phase 2b/3 clinical study will evaluate the efficacy and safety of ABBV-RGX-314 gene therapy in participants with nAMD. The study will evaluate 2 dose levels of ABBV-RGX-314 relative to an active comparator. The primary endpoint of this study is the mean change from baseline in best-corrected visual acuity (BCVA) of ABBV-RGX-314 relative to ranibizumab at Week 54. Approximately 630 participants who meet the inclusion/exclusion criteria, will be enrolled into one of 3 arms.
A bilateral treatment substudy conducted at US sites is an open-label, partially randomized, parallel arm study to evaluate the safety and efficacy of subretinal ABBV-RGX-314 administered bilaterally in participants who have bilateral nAMD. Previously treated crossover participants from the control arm of the main study who crossed over and received ABBV-RGX-314 in the study eye will receive the same ABBV-RGX-314 dose in the contralateral eye (ie, same dose as in the study eye), and newcomers (participants who have not been randomized in an ABBV-RGX-314 study) and untreated crossover participants (ongoing control participants in the main study who have completed Week 54 but have not crossed over to receive ABBV-RGX-314 in the main study) will be randomized in a 2:1 ratio to receive ABBV-RGX-314 Dose 1 or ABBV-RGX-314 Dose 2 in both eyes. Up to 15 participants who qualify for the substudy will be enrolled and followed for a minimum of 50 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria (Bilateral Treatment Substudy)*:
Exclusion Criteria:
Exclusion Criteria (Bilateral Treatment Substudy)*:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABBV-RGX-314 Dose 1 administered via subretinal delivery one time.
Genetic: ABBV-RGX-314
ABBV-RGX-314 Dose 2 administered via subretinal delivery one time.
Genetic: ABBV-RGX-314
Ranibizumab administered via intravitreal injection approximately every 28 days
Biological: Ranibizumab (LUCENTIS®)
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
Also known as: surabgene lomparvovec, RGX-314
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
Also known as: surabgene lomparvovec, RGX-314
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
Also known as: Ranibizumab (anti-VEGF agent)
Mean change from baseline in Best Corrected Visual Acuity (BCVA)
BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)
Time frame: At Week 54
Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEs
Incidence of ocular AEs and any SAEs
Time frame: Week 50
Incidences of ocular and overall AEs over 54 weeks
AEs over 54 weeks
Time frame: Through Week 54
Incidences of ocular and overall AEs over 98 weeks
AEs over 98 weeks
Time frame: Through Week 98
Mean change from baseline in BCVA to Week 98 (ABBV-RGX-314 randomized participants) based on the ETDRS score
BCVA measured by ETDRS
Time frame: Week 98
Proportion of participants with worsened BCVA
Proportion with worsened BCVA
Time frame: Week 54; Week 98
Proportion of participants with improved BCVA
Proportion with improved BCVA
Time frame: Week 54; Week 98
Proportion of participants (1) gaining > 0 letters; (2) losing > 0 letters; maintaining vision (not losing ≥ 15 letters) compared with baseline as per BCVA
Proportion gaining or losing \> 0 letters based on ETDRS score; proportion maintaining vision
Time frame: Week 54; Week 98
Mean change from baseline in BCVA for participants who received 0 or more supplemental anti-VEGF injections (ABBV-RGX-314 randomized participants)
Mean change in BCVA based on ETDRS score for participants who received 0 or more supplemental anti-VEGF injection
Time frame: Week 54; Week 98
Mean change from Week 54 to Week 98 in BCVA (control arm participants who cross over to ABBV-RGX-314)
Mean change in BCVA based on ETDRS score
Time frame: Week 54 to Week 98
Mean change from baseline in CRT as measured by SD-OCT
Mean change in CRT as measured by SD-OCT
Time frame: Week 54; (ABBV-RGX-314 randomized participants) Week 98
Mean change from Week 54 to Week 98 in CRT as measured by SD-OCT (control arm participants who cross over to ABBV-RGX-314)
Mean change in CRT as measured by SD-OCT
Time frame: from Week 54 to Week 98
Mean change from baseline in CPT as measured by SD-OCT
Mean change in CPT as measured by SD-OCT
Time frame: Week 54; (ABBV-RGX-314 randomized participants) Week 98
Mean change from Week 54 to Week 98 in CPT as measured by SD-OCT (control arm participants who cross over to ABBV-RGX-314)
Mean change in CPT as measured by SD-OCT
Time frame: from Week 54 to Week 98
Mean number of supplemental anti-VEGF injections from Baseline through Week 54 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (ABBV-RGX-314 randomized participants and control arm participants who cross over to ABBV-RGX-314)
Mean number of supplemental anti-VEGF injections
Time frame: Through Week 98
Proportion of participants with 0, 1, 2, and 3 supplemental injections through Week 54 and Week 98 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (control arm participants who cross over to ABBV-RGX-314)
Proportion of participants with 0, 1, 2, and 3 supplemental injections
Time frame: Through Week 98
Proportion of participants with ≤ 1, ≤ 2, and ≤ 3 supplemental injections through Week 54 and Week 98 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (control arm participants who cross over to ABBV-RGX-314)
Proportion of participants with ≤ 1, ≤ 2, and ≤ 3 supplemental injections
Time frame: Through Week 98
Proportion of participants that received 1 or 2 injections through Week 54 and Week 98 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 98 (control arm participants who cross over to ABBV-RGX-314)
In the subset of participants who were given supplemental anti-VEGF injections, proportion of participants that received 1 or 2 injections
Time frame: Through Week 98
Proportion of participants with a reduction of ≥ 50% in anti-VEGF injection annualized rate through Week 54 and Week 98 compared with the prior year (ABBV-RGX-314 randomized participants)
Proportion of participants with a reduction of ≥ 50% in anti-VEGF injection annualized rate
Time frame: Through Week 98
Proportion of participants with a reduction of ≥ 75% in anti-VEGF injection annualized rate through Week 54 and Week 98 compared with the prior year (ABBV-RGX-314 randomized participants)
Proportion of participants with a reduction of ≥ 75% in anti-VEGF injection annualized rate
Time frame: Through Week 98
Percent reduction in anti-VEGF injection annualized rate compared with the prior year (ABBV-RGX-314 randomized participants)
Supplemental anti-VEGF injection annualized rate
Time frame: Through Week 54 and Week 98
Supplemental anti-VEGF injection annualized rate through Week 54 and Week 98 (ABBV-RGX-314 randomized participants)
Supplemental anti-VEGF injection annualized rate
Time frame: Through Week 54 and Week 98
Percent reduction in anti-VEGF injection annualized rate after Week 58 through Week 98 relative to the year prior to the study (control arm participants who cross over to ABBV-RGX-314)
Percent reduction in anti-VEGF injection annualized rate
Time frame: After Week 58 through Week 98
Supplemental anti-VEGF injection annualized rate after Week 58 through Week 98 (control arm participants who cross over to ABBV-RGX-314)
Supplemental anti-VEGF injection annualized rate
Time frame: After Week 58 to Week 98
Time to first supplemental anti-VEGF injection after the Week 2 injection (ABBV-RGX-314 randomized participants)
Time to first supplemental anti-VEGF injection
Time frame: Week 98
Time to first supplemental anti-VEGF injection after the Week 58 injection (control arm participants who cross over to ABBV-RGX-314)
Time to first supplemental anti-VEGF injection
Time frame: After Week 58 to Week 98
Mean change from baseline in NEI-VFQ-25 (composite score) at Week 54 and (for ABBV-RGX-314 randomized participants and control arm participants who cross over to ABBV-RGX-314) Week 98
Mean change in NEI VGQ-25 (composite score) at week 54 (control arm participants who cross over to ABBV-RGX-314)
Time frame: Week 54; Week 98
Mean change from baseline in MacTSQ (composite score) at Week 54 and (for ABBV-RGX-314 randomized participants and control arm participants who cross over to ABBV-RGX-314) Week 98
Mean change from baseline in MacTSQ (composite score) at week 54 and (control arm participants who cross over to ABBV-RGX-314) at Week 98
Time frame: Week 54; Week 98
Aqueous ABBV-RGX-314 TP concentrations (ABBV-RGX-314 randomized participants)
Aqueous ABBV-RGX-314 TP concentration
Time frame: Wk -2, Wk 14, Wk 26, Wk 38, Wk 54, and Wk 98
Aqueous ABBV-RGX-314 TP concentrations (control arm participants who cross over to ABBV-RGX-314)
Aqueous ABBV-RGX-314 TP concentration
Time frame: Wk 54, Wk 66, Wk 78, Wk 90, and Wk 98
Immunogenicity measurements (ABBV-RGX-314 randomized participants)
Immunogenicity measurements (serum antibodies to AAV8 and serum antibodies to ABBV-RGX-314 TP)
Time frame: Wk -2, Wk 14, Wk 26, Wk 38, Wk 54, and Wk 98
Immunogenicity measurements (control arm participants who cross over to ABBV-RGX-314)
Immunogenicity measurements (serum antibodies to AAV8 and serum antibodies to ABBV-RGX-314 TP)
Time frame: Wk 54, Wk 66, Wk 78, Wk 90, and Wk 98
Bilateral Treatment Substudy: Incidence of nonocular AEs and any AEs of special interest
Nonocular AEs and AEs of Special interest
Time frame: Week 50
Bilateral Treatment Substudy: Mean change from Baseline in BCVA at assessed timepoints
BCVA measured by ETDRS
Time frame: Through Week 50
Bilateral Treatment Substudy: Mean change from Baseline in CRT at assessed timepoints
Mean change in CRT as measured by SD-OCT
Time frame: Through Week 50
Bilateral Treatment Substudy: Supplemental anti-VEGF injection annualized rate
Supplemental anti-VEGF injection annualized rate
Time frame: Through Week 50
Bilateral Treatement Substudy: Mean number of supplemental anti-VEGF injections
Mean supplemental anti-VEGF injections
Time frame: Through Week 50
Bilateral Treatment Substudy: Proportion of participants with 0, ≤ 1, ≤ 2, and ≤ 3 supplemental anti-VEGF injections
Proportion of participants with 0, ≤ 1, ≤ 2, and ≤ 3 supplemental anti-VEGF injections
Time frame: Through Week 50
Bilateral Treatment Substudy: Aqueous humor and serum ABBV-RGX-314 TP concentrations
Aqueous humor and serum ABBV-RGX-314 TP Concentrations
Time frame: Wk 26, Wk 34, Wk 50
Bilateral Treatment Substudy: Immunogenicity measurements (serum anti-ABBV-RGX-314 TP antibodies, serum anti-AAV8 antibodies) and enzyme-linked immunospot at assessed time points
Immunogenicity measurements
Time frame: Wk 18, Wk 34, Wk 50
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Choroidal Neovascularization →